COMPOUND AS KIF18A INHIBITOR

WIPO Patent Application WO/2022/268230

A1

The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate and solvate thereof. The compound can be used for treating or preventing diseases or symptoms associated with the activity or expression amount of KIF18A.

JP7335341	NLRP3 modulator
JP5642963	Phosphoinositide PDK1 inhibitor
WO/2007/127765	INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

ZHANG HANCHENG (CN)
JIA WEI (CN)
CAI CONGCONG (CN)

PCT/CN2022/101694

December 29, 2022

June 27, 2022

Click for automatic bibliography generation  

HANGZHOU INNOGATE PHARMA CO LTD (CN)

C07D401/14; A61K31/438; A61K31/444; A61K31/4545; A61K31/502; A61K31/506; A61K31/517; A61K31/5377; A61P31/12; A61P31/16; A61P35/00; C07D221/20; C07D401/12; C07D413/12; C07D413/14

WO2021026100A1	2021-02-11
WO2020132649A1	2020-06-25
WO2020132651A1	2020-06-25
WO2020132653A1	2020-06-25
WO2020132648A1	2020-06-25
WO2021026098A1	2021-02-11
WO2021026099A1	2021-02-11
WO2020092187A1	2020-05-07
WO2020132648A1	2020-06-25
WO2021026101A1	2021-02-11
WO2021026098A1	2021-02-11
WO2020132653A1	2020-06-25
WO2020132651A1	2020-06-25

US20200140411A1	2020-05-07
US9527885B2	2016-12-27

ORGANIC LETTERS, vol. 16, 2014, pages 6248 - 6251
HELVETICA CHIMICA ACTA, vol. 64, 1981, pages 1849 - 1853
CHEMICAL COMMUNICATIONS, vol. 57, no. 27, 2021

XU&PARTNERS, LLC. (CN)

View/Download PDF      PDF Help

Previous Patent: PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL ...

Next Patent: METHOD AND APPARATUS FOR PREDICTING WHETHER LESION IS BENIGN OR MALIGNANT BASED ON DECOUPLING MECHAN...